US FDA accepts NDA to review Seysara for treatment of moderate to severe acne

MLA

“US FDA Accepts NDA to Review Seysara for Treatment of Moderate to Severe Acne.” PharmaBiz, Dec. 2017. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.519912951&authtype=sso&custid=ns315887.

APA

US FDA accepts NDA to review Seysara for treatment of moderate to severe acne. (2017, December 22). PharmaBiz.

Chicago

PharmaBiz. 2017. “US FDA Accepts NDA to Review Seysara for Treatment of Moderate to Severe Acne,” December 22. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.519912951&authtype=sso&custid=ns315887.